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Introduction
With approximately 50 million people affected worldwide epilepsy belongs to the most common neurological diseases (World Health Organization, 2015) with a high impact on the quality of life. The prevalence in Western Europe is about 0.5 % with estimated 350,000 new cases each year and even higher corresponding rates in developing countries (World Health Organization, 2015) . Epilepsy is a chronic brain disorder and although progress in the treatment has been made in the last decades, one third of patients do not achieve long-term seizure freedom with currently available antiepileptic drugs (AEDs) (Brodie et al., 2012) . This, taken together with the increased mortality associated with epilepsy (Forsgren et al., 2005) make the disorder an unmet medical need requiring further investigation and the identification of novel drug targets.
So far, compounds enhancing GABA neurotransmission are among the most frequently applied AEDs. As GABA exerts its fast synaptic inhibition through activation of the GABA A receptor, a ligand gated Cl -channel, the strength and polarity of GABA signalling is determined by the Cl -gradient, which in turn is controlled mainly by two cation chloride cotransporters. The Cl -importer Na-K-2Cl cotransporter isoform 1 (NKCC1) and Cl -exporter K-Cl cotransporter isoform 2 (KCC2) together ensure that Cl -is kept at a low intracellular level. One potential reason for the lack of effect of GABA mimetic drugs in epilepsy may be impairments in the Cl -homeostasis. In epileptic neurons the ratio of NKCC1/KCC2 activity is typically upregulated leading to an increased intracellular Cl -load and/or limited Cl -export capacity. Consequently, E GABA is depolarizing, enhancing the probability of neuronal synchrony (Jeong and Gutkin, 2007) and hyperexcitability. Possible causes include changes in the relative expression levels, protein stability and/or kinetic properties affecting NKCC1, KCC2 or both (Löscher et al., 2013) . A large number of genetic, in vitro and in vivo studies on animal models as well as human epileptic tissue provide robust evidence for the role of an impaired Cl -homeostasis in the pathophysiology of seizures and epilepsy. Therefore, therapeutic approaches targeting the Cl -homeostasis may help to overcome the treatment gap. In this respect, bumetanide (3-butylamino-4-phenoxy-5-sulfamoylbenzoic acid), a wellknown potent loop diuretic, gained interest.
Numerous experiments investigating the effect of bumetanide on the Cl -homeostasis and putative anticonvulsant efficacy have already been conducted in a variety of animal models (for review see (Löscher et al., 2013) ). In vitro studies demonstrated that bumetanide induces a hyperpolarizing E GABA shift in immature neurons (Dzhala et al., 2005) and continuous treatment inhibits spontaneous epileptiform activity in hippocampal slices from neonatal kainic acid (KA)-treated rats (Nardou et al., 2009 ). In addition, bumetanide augmented the anticonvulsant efficacy of PB against acute seizures (Dzhala et al., 2008) and restored PB-mediated seizure suppression, which had been lost after seizure-like events (Nardou et al., 2011) . In in vivo experiments epileptogenesis was slowed down and seizure duration decreased after treatment with bumetanide compared to vehicle in the KA-induced post-Status Epilepticus (SE) model in mice. In the same model combination treatment with diazepam successfully suppressed seizures, which are normally benzodiazepine-resistant, supporting the proposed synergistic effect (Sivakumaran and Maguire, 2016) .
However, the induction of diuresis and concomitant risk for hypokalemic alkalosis (Sica, 2004) clearly limit the application of bumetanide for chronic treatment of CNS disorders. Due to active uptake via organic anion transporters (OATs) present in proximal renal tubules the drug rapidly accumulates in the kidney and elicits a potent diuretic effect mainly by blocking NKCC2 transporters, which are concentrated in the ascending loop of Henle (Nielsen et al., 1998; Hasannejad et al., 2004; Kobayashi et al., 2005) . The second major disadvantage is the low bioavailability of the drug in the brain. Only the unionized and unbound form can passively penetrate the blood-brain barrier (BBB), which is about 1 -2 % of the total plasma concentration (Puskarjov et al., 2014; Töpfer et al., 2014) . In addition, active efflux mainly via
OATs present in the BBB (Römermann et al., 2017) reduces the brain level of bumetanide even further making it almost impossible to achieve pharmacologically relevant drug concentrations after systemic application (Puskarjov et al., 2014) . To successfully apply bumetanide for the treatment of neurological and psychiatric disorders these pharmacokinetic constraints need to be overcome.
There are basically two different approaches to improve the pharmacological profile of bumetanide and thereby allow its application for the treatment of epilepsy. One is to use lipophilic prodrugs that more easily penetrate the BBB and are subsequently metabolized to bumetanide once within the CNS . One of those prodrugs, the dimethylaminoethyl ester of bumetanide (BUM5) showed promising results in increasing the seizure threshold after epileptogenic brain insults (SE, kindling) in combination with PB.
Furthermore, it led to higher concentrations of cleaved bumetanide in the brain and caused less diuresis than bumetanide itself Erker et al., 2016) . However, it has recently been shown that BUM5 decreases the survival in a mouse model of stroke. It is assumed that BUM5 causes bumetanide to accumulate in the brain and exert toxic effects when administered at a dose of 13 mg / kg over several days (Huang et al., 2019) .
The second approach, chosen for the present study, is the design of lipophilic bumetanide derivatives that cross the BBB more easily but are not converted to bumetanide. This was achieved by altering the carboxylic acid group, which is mainly responsible for the high ionization at physiological pH and hence the poor BBB penetration. One such drug, BUM690, was first described by Nielsen and Feit (1978) during structure-activity studies of aminobenzoic acids and belongs to the most active compounds in comparison to other benzylamine derivatives. Moreover, the diuretic potency is less than 10 % compared to the parent drug. Bumetanide causes diuresis of 33 ml / kg at a dose of 0.1 mg / kg, whereas BUM690 of only 29 ml / kg at a ten times higher dose of 1 mg / kg in dogs (Nielsen and Feit, 1978) . BUM97 and BUM532 are novel lipophilic bumetanide derivatives that both possess a trifluoro-ethyl group that vastly increases the lipophilicity and in addition seems to be essential for their activity.
The aim of this study was to assess the potential anticonvulsant efficacy of three lipophilic bumetanide derivatives (BUM97, BUM532, BUM690) using in vivo mouse models. These drugs were selected due to their proposed high BBB penetration and lack of diuretic effect.
The antiepileptic effects alone as well as in combination with the established anticonvulsant
GABA-mimetic PB were tested in the KA model of TLE and the pentylenetetrazol (PTZ) model of acute seizures.
Methods

Animals
Young adult male C57BL/6N mice (3 -6 months, Charles River, Sulzfeld, Germany) were used for all experiments. For maintenance animals were group-housed (maximum five mice in individually ventilated type II long cages) with standard laboratory chow and water accessible ad libitum. Mice were kept in a controlled environment with a regular 12 h light/dark cycle (150 lux, light on 7 a.m. to 7 p.m.), room temperature fixed to 23 °C and 60 % humidity. All experimental procedures were approved by the Austrian Animal Experimentation Ethics Board in compliance with the EU Directive 2010/63/EU "on the protection of animals used for scientific purposes". Every effort was taken to minimize both, the number and suffering of mice.
Kainic acid injection and electrode implantation
For intrahippocampal KA injection twelve mice (24 -35 g) were sedated with ketamine (160 mg / kg i.p.; aniMeica GmbH, Germany) and then deeply anaesthetized with 1 -3 % sevoflurane through a precise vaporizer (Midmark, USA). Fifty nL of a 20 mM KA solution (pH 7.2) were injected stepwise into the CA1 area of the left dorsal hippocampus (DV -0.17 mm, RC -0.18 mm, ML ± 0.16 mm from bregma (Paxinos and Franklin, 2001 ) as described elsewhere (Loacker et al., 2007) . Immediately after KA administration mice were implanted with electrodes for in vivo EEG recording. Two depth electrodes made from epoxylite-coated tungsten (diameter 250 µm; FHC Inc., USA) were implanted bilaterally targeting the CA1 area of the hippocampus. Two surface electrodes made from gold-coated screws were placed bilaterally into the skull over the frontoparietal cortex (RC + 0.17 mm, ML ± 0.16 mm from bregma) to monitor seizure spread and one surface electrode over the cerebellum serving as ground and reference. Electrodes were secured in place using dental acrylic cement (Heraeus Kulzer GmbH, Germany). All mice received meloxicam (2 mg / kg i.v.) 20 min before and 12 hrs after surgery as analgesic treatment.
EEG recording and analysis
After a latent period of 3 -6 weeks post KA-induced SE mice developed chronic TLE characterized by spontaneous focal seizures in the ipsilateral hippocampus, which then usually persist life-long with stable frequency and rarely spread over both hemispheres (on average one generalized seizure per day). Treatments started after establishment of selfsustained seizures (about 4 weeks after KA) and finished approximately three months later.
4-channel EEG was recorded in freely moving animals using the wireless Neurologger device (TSE Systems GmbH, Germany) and automatically analysed with the SCIWORKS Software (Datawave Technologies, USA) (Zangrandi et al., 2016) . The EEG trace obtained from the ipsilateral depth electrode was filtered for three types of abnormal epilepsy-like activity (Suppl. Fig. 1 ). Epileptiform spikes were defined as brief (< 70 ms) high amplitude (> 3 x baseline) discharges. At least three spikes with a frequency > 1 Hz lasting a minimum of 1 s were counted as spike trains. Spike trains longer than 10 s were defined as hippocampal paroxysmal discharges (HPDs; (Riban et al., 2002) ). Spikes detected between spike trains and HPDs were defined as inter-ictal spikes. All treatments were applied at 3 p.m.
(i.p. injection, 10 ml / kg fixed volume) with the EEG recordings performed between 2 -5 p.m.
to assess the baseline epileptic activity in one hour pre-treatment and subsequent two hours post-treatment to conclude upon drug effects. EEGs displaying less than 100 s of epileptiform activity during 60 min baseline recording or a generalized seizure were excluded from analysis. Therefore, group sizes may vary. At least 72 h were between drug applications. Data are presented as ratio of events in the first hour after treatment compared with the last hour before treatment. In addition, the dose-response over time is depicted.
Pentylenetetrazole-induced seizure threshold
Acute seizures were induced in 79 naïve mice (25 -42 g) by infusion of PTZ (10 mg / ml in saline) into freely moving animals via the tail-vein at a constant flow rate of 100 µl / min.
Seizure threshold was determined 30 min after i.p. injection of either different doses of the compounds alone or in combination with PB in a fixed volume of 10 ml / kg body weight.
Saline injected animals were used as control. Immediately at the first appearance of a generalized seizure PTZ infusion was stopped and mice were sacrificed by cervical dislocation. Based on the PTZ volume required and the animal's body weight the threshold was calculated.
In situ Hybridization
In situ Hybridization (ISH) for NKCC1 expression was performed on 20 µm thick coronal section (bregma -1.8 mm) obtained from snap-frozen brains of 7 control and 8 epileptic mice as described elsewhere (Wittmann et al., 2005) . Briefly, single-stranded DNA oligonucleotides (2.5 pmol / µl; 5' -AGAAGGCACCTCAAGGCTAAAGGCTTTGCACTC CTTTCAGCAATC-3') complementary to the mRNA of NKCC1 were radiolabeled by incorporation of 35 SdATPs (Perkin Elmer, Massachusetts, USA) at the 3'-end using deoxynucleotidyltransferase. Hybridization was performed at 52 °C over night. After exposure to a radiographic film for 13 days, the autoradiographs were analysed with ImageJ (NIH; version 1.51s). The relative optical density (ROD) was calculated from the grey value of the dentate gyrus of the ipsilateral (injected) hippocampus and the background obtained over the caudate putamen was subtracted. In addition, the extent of granule cell dispersion (GCD) as typical morphological alteration in an epileptic hippocampus was scored and correlated with the treatment response of the animal to 10 mg / kg BUM97.
Data and statistical analysis
For statistical analysis as well as figure generation GraphPad prism 5 for Mac (version 5.0f) was used. Data from the PTZ seizure threshold test were analysed using One-way ANOVA 
Chemicals
The NKCC1/NKCC2 antagonist bumetanide (Alchem Pharmtech Inc. NJ 08852 U.S.A) as well as the three bumetanide derivatives were dissolved in fresh DMSO (10 mg / ml) and further diluted with 0.9 % saline (with 3 % Tween80) to obtain doses of 1, 3 and 10 g / kg while keeping 10 % DMSO concentration for all dilutions. The GABA A R-antagonist PTZ and the anticonvulsant drug PB were purchased from Sigma Aldrich (St. Louis, USA); KA from Ocean Produce International (Shelburne, Canada). All three were dissolved in 0.9 % saline.
All chemicals used for the synthesis of bumetanide derivatives were purchased from commercial suppliers (Sigma Aldrich, Apollo Scientific, Fluorochem and TCI Europe) at analytical grade. To monitor reactions via thin layer chromatography, silica gel F254 coated aluminum sheets from Merck were used. As a stationary phase for column chromatography silica gel 60 (70 -230 mesh ASTM; Merck) was used. Mass spectra were recorded on a Shimadzu (GC-17A; MS-QP5050A) spectrometer. The peak intensity is specified in percent relative to the biggest signal in the spectrum. Highresolution mass spectra were performed on a MALDI-q/q-TOF-spectrometer (Bruker maxis HD)
Results
Synthesis of lipophilic bumetanide derivatives
The three derivatives tested in vivo in this study were selected based on their higher BBB passage together with the lack of a diuretic effect as proposed in silico. By contrast to the benzylamine derivative BUM690, BUM532 and BUM97 are novel compounds that possess a trifluoro-ethyl instead of the allyl-group, which is assumed to improve the pharmacological profile compared to BUM690 (Fig. 1) . As in vivo experiments identified BUM97 as the most promising derivative out of the three compounds tested (see below), only the BUM97 synthesis will be described in detail here, whereas the synthesis of BUM532 and BUM690
can be found in the supplementary material. To produce BUM97 (3-(Butylamino)-2-phenoxy-5-(2,2,2-trifluoroethoxymethyl) benzenesulfonamide) 2 mmol (84 mg) of a dispersion of sodium hydride in mineral oil (60 %) were washed two times with dry THF in a three necked round bottom flask. Then 3 ml THF, 1.5 mmol (108 µl) 2,2,2-trifluorethanol and 0.5 mmol (184 mg) of 3-(butylamino)-5-(chloromethyl)-2-phenoxy-benzenesulfonamide (synthesis described in supplementary material) were added to the sodium hydride. The reaction mixture was stirred at room temperature overnight. After the reaction was completed it was quenched with 3 ml water. The mixture was then extracted three times with ethyl acetate, the combined organic layers were washed with brine, dried over 7, 142.2, 137.3, 135.8, 134.7, 129.0, 124.5 (q, J = 279.2 Hz), 121.9, 115.5, 113.9, 113.0, 72.9, 66.6 (q, J = 32.8 Hz), 42.0, 30.3, 19.3, 13.6 6.68 %
BUM97 induces a long-lasting suppression of epileptic discharges in KA-treated mice
The anticonvulsant effects of the derivatives were investigated in the unilateral KA mouse model of TLE. Treatment effects on epileptiform discharges were calculated as the ratio of events (number of spikes; duration and number of spike trains or HPDs) in the first and second hour after drug application, respectively, compared to the events in 60 min pre treatment (Table 1; Figs. 2 -4; Suppl. Table 1 ). Whereas spike trains and HPDs are both described as high-frequency and high-amplitude EEG activity, only HPDs are considered a model of therapy-resistant focal seizures (Riban et al., 2002; Zangrandi et al., 2016) .
Therefore, HPD suppression has a high predictive value for the development of drugs targeting treatment-resistant epilepsy. Representative EEG traces obtained for the treatment effects on epileptiform activity are depicted in Fig. 3G .
Mice treated with PB alone showed no suppression of spike trains or inter-ictal spikes (Table 1 ) but the number of HPDs was significantly reduced compared to vehicle ( Fig Interestigly, when combined with PB strong inter-individual variability was observed.
BUM532 did not reveal any effects on spike trains in KA injected mice compared to vehicle treatment (Table 1A) . However, already the lowest dose of BUM532 efficaciously suppressed the number of HPDs (Fig. 2C left; One-way ANOVA; 1 mg / kg 82.2 ± 22.1 %; p < 0.01; 3 mg / kg 62.1 ± 31.5 %; p < 0.001; 10 mg / kg 68.2 ± 12.6 %; p < 0.001). However, no more than about 50 % reduction in epileptiform activity was observed. Also the combination with PB did not yield an additional synergistic effect (One-way ANOVA; 10 mg / kg + 10 mg / kg PB 64.4 ± 8.9 %, p < 0.001; F 4, 17 = 11.29). The reduction in the number of HPDs was associated with a significant decrease of the total time spent in HPDs (Fig. 2C right; One-way ANOVA;
1 mg / kg 72.3 ± 31.8 %; p < 0.05; 3 mg / kg 59 ± 38 %; p < 0.01; 10 mg / kg 58 ± 14.7 %; p < 0.01; 10 mg / kg + 10 mg / kg PB 54.8 ± 9.7 %; p < 0.01; F 4, 17 = 7.58). Interestingly, application of 3 mg / kg BUM532 and the combined treatment with PB induced a significant increase in the number of inter-ictal spikes compared to vehicle treatment (Table 1B ; Oneway ANOVA; vehicle 93.1 ± 24.5 %; 3 mg / kg 136.5 ± 23.7 %, p < 0.01; 10 mg / kg + 10 mg / kg PB 132.2 ± 35.2 %; p < 0.05; F 4, 23 = 4.37).
BUM97 alone as well as in combination with PB suppressed the number of spike trains within the first hour in epileptic animals (Suppl. Table 1 ; One-way ANOVA; 10 mg / kg 55.6 ± 31.2 %, p < 0.01; 10 mg / kg + 10 mg / kg PB 49.5 ± 19.4 %, p < 0.01; F 4, 33 = 4.22) compared to vehicle treatment (105.6 ± 35.5 %). For the total time spent in spike trains significance was reached even with a lower BUM97 dose and increased dose-dependently (Table 1A ; Oneway ANOVA; 3 mg / kg 62.5 ± 19.9 %, p < 0.05; 10 mg / kg 40.6 ± 30.2 %, p < 0.001; 10 mg / kg + 10 mg / kg PB 28.6 ± 30.2 %, p < 0.001; F 4, 33 = 8.88) compared to treatment with vehicle (98 ± 29.7 %). This suggests that the reduction of the total time spent in spike trains does not only result from a lower spike train frequency but is also due to a lower average duration of spike trains. BUM97 dose-dependently reduced the number ( (Riban et al., 2002; Zangrandi et al., 2016) . In line with these findings, injection of BUM97 showed no effect on inter-ictal spikes (Table 1B) . The primary aim of this study was to compare the anticonvulsant properties of bumetanide derivatives with the mother compound. Therefore, we compared the most efficacious dose of each derivative with bumetanide either alone or in combination with PB. Two-way ANOVA analysis on the post-treatment period revealed that the suppression of spike trains was more pronounced and longer lasting for BUM97 compared to the other derivatives and bumetanide (Fig. 3E ). Comparing the time courses for the number of spike trains statistical significance was revealed for variables time (F = 12.37; p < 0.001) and treatment (F = 3.38; p < 0.05), but not for the time*treatment interaction compared to bumetanide. Bonferroni post hoc test showed that treatment with 10 mg / kg BUM97 suppressed spike trains significantly stronger than bumetanide in the 15 -30 min (bumetanide 113.3 ± 31.3 %; 10 mg / kg BUM97 57.1 ± 45.1 %; p < 0.05) and 45 -60 min (bumetanide 124.1 ± 39.7 %; 10 mg / kg BUM97 71.3 ± 39.3 %; p < 0.05) interval after drug injection. These results were confirmed analyzing the time courses of the total time spent in spike trains (Suppl. Fig. 2E ; F = 16.54; p < 0.001 for time; F = 3.66; p < 0.01 for treatment; no significance for time*treatment interaction).
Comparing the co-administrations the reduction of epileptiform discharges was strongest upon treatment with BUM97 with PB, followed by BUM532 and bumetanide with PB ( Fig. 3F; Suppl. Fig. 2F ). In contrast to the highest doses applied alone, Two-way ANOVA revealed significant effects on the main factors time and treatment for both, the number (F = 9.43; p < 0.001 for time; F = 9.08; p < 0.001 for treatment) and time spent in spike trains (F = 9.16; p < 0.001 for time; F = 7.53; p < 0.01 for treatment). Additionally, treatment responses varied significantly between animals for the time spent in spike trains (F = 3.08; p < 0.01) but not for their number. Neither for the number nor for the time spent in spike trains an effect on the time*treatment interaction was revealed. Post hoc analysis showed no significant differences between individual 15 min intervals compared to bumetanide with PB.
NKCC1 expression is upregulated in epileptic animals
The rational of using bumetanide in the treatment of epilepsy is based on its inhibitory function on NKCC1. To investigate the expression of NKCC1 in the KA model we performed ISH using probes against NKCC1. In line with previous reports, epileptic animals showed a significant upregulation of NKCC1 in the granule cell layer (GCL) of the hippocampus compared to controls ( Fig. 4A ; Mann Whitney test; control ROD 0.052; KA-treated ROD 0.1025; p < 0.01).
All mice except of one, which was subsequently excluded from the analysis of drug effects, showed the typical neuropathological changes reported in epileptic animals generated by intracerebral injection of KA. Most prominently visible in the ipsilateral hippocampus were the dispersion of granule cells and extensive neuronal loss in the CA1 and CA3 hippocampal areas. Consistent with literature those animals with the most pronounced morphological alterations were also the ones with the highest amount of epileptiform discharges, especially HPDs, in the EEG recordings.
For nearly all applied treatments high inter-individual variability in the efficacy and duration of treatment responses was observed. As an example, Suppl. Fig. 3 depicts the responses of the individual mice to treatment with 10 mg / kg BUM97, the most promising monotherapy.
While some animals showed a sustained suppression of epileptiform activity ("longresponders"), in others the epileptic discharges were back to baseline activity already after about one hour ("short-responders"). These differences did not correlate to the expression level of NKCC1 mRNA (data not shown). To test whether these differences could be associated with the extent of neuropathological alterations the degree of GCD in the lesioned hippocampus was scored between 0 and 3 (from no dispersion to a strong broadening of the GCL, respectively; Fig. 4C ). The dispersion scores were then correlated to the number of spike trains recorded in the second hour after administration of 10 mg / kg BUM97. The obtained plot reveals a correlation of GCL dispersion and duration of treatment (Fig. 4B) .
Effects on acute seizures
To None of the compounds applied alone altered the PTZ threshold dose compared to vehicle injection ( Fig. 5A-D) , nor did the combination of bumetanide or BUM97 with PB.
Besides assessing the anticonvulsant also diuretic and potentially adverse effects of the derivatives were studied. For that, animals were placed in a PVC box without bedding 30 min after the application of the highest dose of each derivative and vehicle and the number of urine drops expelled in 10 min was counted. Behavior was observed and ambulation was measured by tracking the distance travelled. One-way ANOVA revealed no statistically significant differences in the diuretic effect of any of the compounds compared to vehicle (vehicle 0.7 ± 0.9 urine drops; 10 mg / kg BUM690 1 ± 1 urine drops; 10 mg / kg BUM532 0.9 ± 0.9 urine drops; 10 mg / kg BUM97 0.7 ± 0.9 urine drops). The distance travelled was reduced after treatment with 10 mg / kg BUM532 or BUM97 as compared to vehicle (Suppl. Fig. 4 ). Besides this, no obvious behavioral effects were observed.
Discussion
NKCC1 has recently been put forward as potential antiepileptic drug target. Indeed, numerous in vivo and in vitro studies with the well-characterized NKCC1/NKCC2-antagonist bumetanide showed a reduction of epileptiform discharges, which underlines the principal feasibility of this therapeutic approach. However, the low BBB penetration and high diuretic effect limit the chronic use in epilepsy treatment. The main objective of this study was to assess the anticonvulsant potential of three bumetanide derivatives (Fig. 1 ), which were selected by two major criteria: First, to facilitate the BBB penetration the compounds should have a higher lipophilicity than bumetanide. In addition, they should not be prodrugs easily metabolized to bumetanide to avoid the diuretic potential. Based on previous studies from Nielsen et al. (1975) on the structure-activity relationships of aminobenzoic acids it was already known that benzylamine-derivatives of bumetanide exhibit a potential for biologic activity possibly caused by NKCC inhibition, just like bumetanide. We chose to study BUM690 because it ranked among the three most potent benzylamine derivatives inducing strong biologic effects. It was recently reported that another benzylamine derivative (5-(anilinomethyl)-3-(butylamino)-2-phenoxy-benzenesulfonamide, also called BUM13/bumepamine) is potent in enhancing the anti-seizure efficacy of PB (Brandt et al., 2018) . However, bumepamine still causes a certain amount of diuresis and does not exhibit any anticonvulsant effect by itself. Starting from BUM13 and BUM690 we altered the structure first by the introduction of a trifluoroethylamino-methyl group and two smaller variations leading to BUM532. This substance already expressed a superior pharmacological profile than either one of the previous compounds. In a second step the nitrogen was exchanged for oxygen yielding BUM97, a novel benzylether derivative of bumetanide that establishes a new class of derivatives not described in literature yet. BUM97 possesses remarkable pharmacological properties and a strong anticonvulsant effect by itself. The trifluoroethyl-group further increased the lipophilicity to a logP of 3.93 (BUM532) and 3.71 (BUM97) compared to 3.17 (BUM690) and 2.53 (BUM13) (MarvinSketch (version 18.10, calculation module developed by ChemAxon, https://chemaxon.com/products/ marvin), 2019), which might explain the improved treatment effects. As BUM532 and BUM97 display great similarity in their structure and lipophilicity, we expected comparable drug effect. The strong effect of BUM97 was rather surprising.
We assessed the effects of multiple doses of the derivatives and the parent drug bumetanide alone as well as in combination with PB using mouse models of acute seizures and chronic TLE. The range of doses for all in vivo experiments was selected based on previous doseresponse studies. Löscher and colleagues showed that 10 mg / kg bumetanide are required to achieve a cerebrospinal fluid (CSF) concentration sufficient for NKCC1 inhibition . In the present study, we tested the derivatives at the same and lower doses.
For PB a dose at the lower border of the therapeutic dosage range was used (10 mg / kg) (Patsalos et al., 2008) .
We chose to work with the intra-hippocampal KA-induced post-SE model of TLE in mice as the KA model not only closely resembles human TLE with similar seizure semiology and neuropathological alterations but has also been extensively characterized regarding EEG abnormalities and their pharmacological responsiveness. Especially HPDs, a type of focal ictal event, proved to be resistant to established AEDs and hence serve as model for the development of novel drugs with efficacy against therapy-resistant focal limbic seizures (Riban et al., 2002; Zangrandi et al., 2016) . As expected from previous research, PB alone moderately decreased spontaneous epileptiform discharges (Regesta and Tanganelli, 1999; Hosseini and Mirazi, 2015) . High doses of bumetanide (> 5 mg / kg) yield a CSF concentration within the IC 50 range (100 -300 nM) necessary for NKCC1 inhibition (Yang et al., 2013) and are thus anticonvulsive (for review see (Rautio et al., 2008; Kahle et al., 2014) ).
In line with this, we observed a moderate but significant suppression of spike trains as well as HPDs by 10 mg / kg bumetanide. However, we did not replicate the proposed potentiation of the anticonvulsant efficacy of PB reported in numerous studies (e.g. see (Kimiskidis and Valeta, 2012; Yang et al., 2013; Bruining et al., 2015) ). But our finding is in accordance with a comparable work from Erker et al., who did not demonstrate a synergistic effect in adult epileptic mice either (Erker et al., 2016) .
For the three bumetanide derivatives tested in this study the results obtained were diverse.
BUM690 was proconvulsive and has thus no therapeutic potential. BUM97 and BUM532 both suppressed epileptiform discharges but differed markedly from each other in their dose-response, efficacy and synergistic effect. BUM532 reduced HPDs at lower doses compared to BUM97 but the maximal effect was smaller, the response short-lasting and adding PB had no additional value. By contrast, already BUM97 alone reduced epileptic discharges to about 20 % and combined treatment with PB nearly completely abolished HPDs. Another decisive advantage of BUM97 is that higher doses alone and combined with PB induced a sustained suppression of epileptiform activity for up to two hours post treatment. This reduction was not only significant compared to vehicle but even more importantly compared to bumetanide. Further, the reduction of spike trains and HPDs was paralleled by an increase in the number of inter-ictal spikes, which is consistent with reduced brain activity following epileptic discharges (Chiang et al., 2018) . Together, based on the findings from the KA model we suggest that out of the three derivatives tested BUM97 is the most promising compound for TLE treatment.
A more detailed analysis of the EEG traces revealed another interesting aspect. Focusing on the time immediately following the drug administration showed that it took several minutes until the onset of the anticonvulsant effect. This is in line with the fact that time is required until a new Cl -homeostasis is established. Until this is achieved, PB initially might only exert a limited anticonvulsant function or be ineffective depending on the polarity and strength of the Cl -gradient. To avoid the possible undesired effects at the start of the treatment the derivatives and PB should be given in sequential order with the former augmenting the efficacy of the latter. That combining the drugs in that way improves the treatment outcome has not only been suggested in literature but the benefit has already been proven in several studies (Rautio et al., 2008; Slaughter et al., 2013) .
Animal models of epilepsy as well as patients are known for pronounced intra-individual variability in the epileptic activity within and between days (Potschka, 2012) as well as strong inter-individual variability in the drug responses (Mohanraj and Brodie, 2013; Malmgren and Edelvik, 2017; Tang et al., 2017) . This was also evident for all treatments applied in this study and explains why significance was only reached for a limited number of time intervals when comparing BUM97 treatment with vehicle or bumetanide, respectively. Also in clinics it is frequently observed that patients with apparently the same type of epilepsy differ markedly in their responsiveness to the same AED so that two subgroups, responders vs. nonresponders, can be distinghuished (Pinard et al., 2010; Mathon et al., 2015) . We assessed whether this pattern is reflected in the treatment response to 10 mg / kg BUM97. Indeed, whereas epileptiform activity was strongly suppressed in all animals in the first hour after treatment, only in a subgroup the response lasted for the entire recording period, defined as less than 20 % HPDs in the second hour post treatment (Suppl. Fig. 3 ). Interestingly, animals with a higher number of HPDs, i.e. more severe epilepsy, were the ones responding with sustained seizure suppression.
Because the amount of target available for drug binding is one of the major factors determining the efficacy of a drug, we hypothesized that the pharmacological responsiveness of epileptic animals to an NKCC1 inhibitor depends on the level of NKCC1 expression.
Although the mouse KA model is well-characterized, data regarding this aspect is sparse.
Therefore, we examined the NKCC1 expression in the chronic phase in KA-treated mice.
Because the CA1 area is nearly completely destroyed in animals with severe epilepsy, we focused on the DG, which is less prone to cell death. Compared to non-epileptic animals the NKCC1 mRNA level was significantly elevated (Fig. 4A) , which can be ascribed to an increase of NKCC1 in granule cells. What needs to be kept in mind when analysing these data is the dispersion of the GCL. Because the mean intensity along a line of fixed length through the apex of the DG was measured, it can be assumed that the already significant upregulation is even an underestimation of the effect. But as the extent of GCD varies widely between the animals and depends on the severity of seizures, the ability to directly correlate the treatment response to BUM97 with the level of NKCC1 expression is limited and did not reach significance (data not shown). However, the data revealed a significant correlation between the treatment response and the extent of GCD with the "long-responders" being those animals with pronounced GCD (score 3), whereas "short-responders" displayed little (score 1) or intermediate (score 2) GCD. So, besides a correlation between the treatment response and amount of epileptic discharges, there is also one between the response and the extent of GCD. This is an interesting observation, especially in view of findings from tissue resected from therapy-resistant patients that demonstrated that hippocampi with GCD had an increased NKCC1 expression within the GCL compared to hippocampi without GCD (Hesdorffer et al., 1996) . Moreover, a high amount of seizures and pronounced morphological alterations have usually been associated with therapy-resistance (Ben-Ari et al., 1980; Kanner, 2002; Itoh et al., 2015; Dostovic et al., 2016) . Future research is required to validate these initial results as that can influence the selection of those patients that might benefit from the treatment with an NKCC1 inhibitor.
To further strengthen our hypothesis that morphological and functional alterations present in epileptic brains are essential for the mechanism of action of bumetanide derivatives, we tested the treatment effects in the PTZ model of acute seizures. Töllner et al. (2014) demonstrated the peak in the bumetanide plasma as well as brain concentration 30 min after systemic administration and also in our KA study the seizure suppression peaked about 30 min after i.p. injection of the derivatives. Based on that, the acute seizure threshold was measured at this time point after i.p. drug application. In line with previous studies, 10 mg / kg PB alone did not alter the seizure threshold compared to vehicle pre-treatment. Also, neither a low nor a high dose of bumetanide alone or in combination with PB were effective.
This again is consistent with literature (Lamberts et al., 2013; Yang et al., 2013) , which reports no anticonvulsant efficacy of bumetanide in the maximum electroshock -as well as PTZ-model in adult mice with doses up to 75 mg / kg (Cho, 2012; Peng et al., 2017) .
Previously studied bumetanide derivatives alone did not alter the acute seizure threshold but potentiated the effect of a sub-threshold dose of PB (Lamberts et al., 2013; Yang et al., 2013) . A similar pattern was observed for the novel compound BUM532, which applied alone had no effect, but combining 10 mg / kg with PB significantly increased the seizure threshold.
By contrast, BUM97 and BUM690 were both ineffective alone and BUM690 induced proconvulsant effects when combined with PB. This lack of effect is in accordance with the proposed mode of function of bumetanide. In the PTZ model acute seizures are induced in healthy animals. However, chronic recurrent seizures cause long-term changes that can impact the efficacy and tolerability of AEDs. In the case of bumetanide there is tentative evidence that they are required for the compound to exert its anticonvulsant function.
Besides alterations in the BBB, numerous studies indicate an impaired Cl -homeostasis and upregulation of NKCC1 in epilepsy. For example, recent experiments in epileptic rodents, who experienced a pilocarpine-induced SE, showed that combining PB with bumetanide, BUM5 or bumepamine significantly increased the PTZ seizure threshold, whereas the same treatments were ineffective in healthy animals (Lamberts et al., 2013; Yang et al., 2013) .
To confirm or refute the observed correlations between seizure severity, extent of neuropathology, NKCC1 expression and anticonvulsant efficacy of bumetanide derivatives would also be important because of the growing doubts about the mechanism of action of bumetanide and its derivatives. There is clear evidence for the anticonvulsant effects of several compounds including BUM97 and BUM532 studied here, but also BUM5 and bumepamine, which were tested by Löscher and colleagues (Mandhane et al., 2007; Yang et al., 2013; Khan et al., 2018) . All these promising substances were derived from bumetanide via chemical modification with the aim to overcome the pharmacological constrains that currently limit the utility of bumetanide for chronic epilepsy treatment. Accordingly, their function was attributed to the structural similarities shared with the parent drug and hence inhibition of the same cellular target, namely NKCC1. The resulting decrease in [Cl - ] i was proposed to be the underlying anticonvulsant mechanism. But this widely accepted hypothesis is increasingly challenged. A number of studies report successful seizure suppression even though the brain concentration necessary for NKCC1 inhibition was certainly not reached (Stödberg et al., 2015) . Furthermore, the derivative bumepamine potentiated the anticonvulsant effect of PB although it has now been proven that the compound is neither converted to bumetanide nor inhibits NKCC1 (Brandt et al., 2018) .
These findings argue for the existence of a yet unidentified, additional or alternative highaffinity target either in the CNS or periphery that contributes, at least partially, to the anticonvulsant action.
Also to us it seems rather unlikely that the substantially higher anticonvulsant efficacy of BUM97 compared to the parent drug bumetanide and the almost doubled effect of PB can solely be ascribed to the improved pharmacokinetic profile. At this stage of understanding it is difficult to propose, which targets and mechanisms are underlying the effects that we report. Although we could not show a correlation between the amount of NKCC1 and the treatment response, we still assume that BUM97 exerts its anticonvulsant effect by acting on the Cl -homeostasis. The transport kinetics of both main Cl -cotransporters in central neurons, NKCC1 and KCC2, are strongly modulated by post-translational modifications. Especially phosphorylations of key threonine residues by the WNK-SPAK/OSR1 kinase cascade have a major impact on the transport activity of cation-chloride cotransporters. Hence, it is difficult to draw conclusion on the Cl -homeostasis by assessing only their expression level. Instead a key mechanism of the anticonvulsant properties of these compounds might be an effect on an upstream regulatory pathway. To date the only sparse pharmakodynamic data available were obtained from two related benzylamine compounds, bumepamine, which did not inhibit NKCC directly but increased the anti-seizure efficacy of PB (Brandt et al., 2018) and STS66, which seems to inhibit the WNK-SPAK/OSR1 upstream regulatory pathway of cation-chloride cotransporters (Huang et al., 2019) . Because it significantly reduced phosphorylated NKCC1, the inhibition occurs most probably at the level of SPAK. Moreover, STS66 seems not to be converted to bumetanide. In addition, also our data show that the compound BUM690 clearly has a novel off-target effect. Because of this accumulating evidence suggesting an unidentified target, the pharmacokinetics and pharmacodynamics of BUM97 need to be further studied.
To our knowledge, this is the first proof of anticonvulsant efficacy of bumetanide derivatives with improved pharmacological profiles on spontaneous recurrent seizures in an in vivo animal model. In two steps the benzylamine compound BUM690, which was first described by Nielsen and Feit (1978) , was altered: First the allyl group of BUM690 was exchanged for a trifluoroethyl group, leading to BUM532. In a second step the nitrogen was exchanged for oxygen resulting in a trifluoroethyoxy subunit in the novel compound BUM97. In conclusion, our data demonstrate the successful considerations concerning the optimization of bumetanide derivatives and the potential of BUM97 for the treatment of therapy-resistant TLE, already as monotherapy but in particular in combination with a GABA mimetic drug. Figure 1 . Bumetanide and its lipophilic derivatives. To increase the lipophilicity the carboxylic acid group of bumetanide was modified. The benzylamine derivative BUM690 (Nielsen and Feit, 1978) was optimized in two steps to yield the two novel compounds BUM532 and BUM97. First the allyl group of BUM690 was exchanged for a trifluoroethyl group (BUM532), then the nitrogen was exchanged for oxygen (BUM97). Table 1 . Drug effects on the time spent in spike trains (A) and the number of inter-ictal spikes (B) in epileptic mice. Compounds were applied i.p. either alone or in combination with 10 mg / kg phenobarbital. Ratios of recorded events 60 min post treatment / 60 min pre treatment from the ipsilateral hippocampus are given. One-way ANOVA with Dunnett's post hoc test (*P < 0.05; **P < 0.01; ***P < 0.001; significantly different from vehicle). Data are expressed as mean ± SD (n = 4 -10). PB, phenobarbital; Bum, bumetanide
Spike Trains
Vehicle Phenobarbital Bum Bum + PB 98 ± 30 % (n = 9) 81± 32 % (n = 9) 65 ± 36 % (n = 7) 73 ± 18 % (n = 5) 1 mg / kg BUM690 3 mg / kg BUM690 10 mg / kg BUM690 BUM690 + PB 80 ± 32 % (n = 6) 60 ± 30 % (n = 3) 95 ± 34 % (n = 7) 108 ± 35 % (n = 5) 1 mg / kg BUM532 3 mg / kg BUM532 10 mg / kg BUM532 BUM532 + PB 81 ± 9 % (n = 5) 73 ± 24 % (n = 6) 69 ± 26 % (n = 5) 71 ± 6 % (n = 4) 1 mg / kg BUM97 3 mg / kg BUM97 10 mg / kg BUM97 BUM97 + PB 75 ± 24 % (n = 6) 63 ± 20 % (n = 7)* 41 ± 30 % (n = 10)*** 29 ± 19 % (n = 6)***
Inter-ictal Spikes
Vehicle Phenobarbital Bum Bum + PB 93 ± 25 (n=9) 108 ± 20 % (n = 9) 118 ± 32 % (n = 6) 100 ± 14 % (n = 4) 1 mg / kg BUM690 3 mg / kg BUM690 10 mg / kg BUM690 BUM690 + PB 92 ± 13 % (n = 6) 87 ± 18 % (n = 5) 94 ± 9 % (n = 7) 119 ± 20 % (n = 5) 1 mg / kg BUM532 3 mg / kg BUM532 10 mg / kg BUM532 BUM532 + PB 94 ± 11 % (n = 4) 137 ± 24 % (n = 6)** 106 ± 18 % (n = 5) 132 ± 35 % (n = 4)* 1 mg / kg BUM97 3 mg / kg BUM97 10 mg / kg BUM97 BUM97 + PB 94 ± 21 % (n = 6) 102 ± 28 % (n = 8) 131 ± 44 % (n = 10) 142 ± 51 % (n = 6) 1, 142.6, 136.5, 136.0, 135.9, 130.2, 123.7, 115.9, 115.4, 115.0, 45.8, 43.2, 31.1, 19.9, 13.8 . MS: m/z: 368/370 M+ To synthesized BUM690, in a next step 1 mmol (369 mg) of the derived product was dissolved in 3 ml allylamine and stirred at room temperature for two days. After the reaction was completed, the solvent was removed under reduced pressure and the crude product 142.5, 137.3, 136.4, 135.8, 135.6, 129.1, 122.3, 116.1, 115.3, 115.2, 114.2, 52.0, 50.9, 42.4, 30.8, 19.5, 12.7 To do that 10 mmol (3.56 g) of 4-(4-fluorophenoxy)-3-nitro-5-sulfamoyl-benzoic acid {WO Patent No. 018635A2, 2012} and 50 mg palladium on activated charcoal (5 % Pd/C) were added to an aqueous solution of LiOH (adjusted to pH 11). The resulting mixture was hydrogenated at room temperature. When the H 2 uptake became negligible, the mixture was filtered and the filtrate was acidified with 6 N HCl and extracted with ethyl acetate three times.
The combined organic layers were washed with brine, dried over Na 2 SO 4 and the solvent was removed under reduced pressure to yield 2.15 g of a brown solid (66 % yield). 
